2024-12-31-accounts

Diabetes Research and Wellness Foundation (A Company Limited by Guarantee) Charity Number: 1070607 Company Number: 03496304 Financial Ststements For the year ended 31-Dec-24

Diabetes Research and Wellness Foundation INDEX Page Report of the Trustees 1to28 Independent Auditors, Report 29to32 statement of Financial Activities 33 Balance Sheet 34 Statement of Cash Flows 35 Notes to the Financial Statements 36to44

Diabetes Research Wellness Foundation Diabetes Research and Wellness Foundation (DRWF) {A Company Limited by Guarantee) REPORT & FINANCIALSTATEMENTS For the year ended 31 December 2024 R￿IStered Charity Number.. 1070607 Company Number: 03496304 pi THANK YOU ! To everyone who has donated, volunteered their time, or undertaken an activity to support us. Your contribution makes all the difference, meaning that we can carry out awareness, educational programmes and research funding activities to ensure that people with diabetes are 'Stoying well until a cure isfound... THANK YOU! for being part of a powerful community who are intent on investing in a brighter future for all people with diabetes

StrongerTogether #UnitedThroughDiabetes

Irrforn￿tl0 Creator

Diabete5 Research Wellness Foundation Message from Co-Founder & Chairman John Alahouzos I would like to dedicate this message to DRWF Co-Founder and Chairman, and my best friend, Walter Michael (Mike) Gretschel who passed away peacefully in early December 2024. Mike was bom and raised in the Washington DC area and had a long and successful career in advertising and marketing. We worked together at the same agency and eventually started our own agency. In 1978 shortly after his son, Christian, was diagnosed with type I diabetes, we devoted all our pro bono efforts to raising funds to find a cure for diabetes, as volunteers and board members of several diabetes charities. In 1993, Mike's passion to fund and find a cure for diabetes inspired u5 to co-found the Diabetes Research & Wellness Foundation IDRWFI in Washington DC, wwth DRWF (UK) being set up just 5 years later in 1998. Mike's mission to fund diabetes research and sUPPOrt projects that had potential to fast-track to a cure, never wavered. He envisioned a future where people living with diabetes received the ongoing education and support needed to stay well and enjoy the best quality of life. Hence the DRWF strapline of 'Staying welluntil a cure isfound... This vision underpins all the DRWF Diabetes Wellness activities, such as our annual programme of Wellness Events, delivery of our quarterly newsletter Diabetes Wellness News, and the research we fund in the UK and around the world. DRWF UK has raised more than £80 million since inception in 1998 and funded some of the most innovative and impactful research that the diabetes community has benefitted from in the last 25 years. such as the DRWF Islet Isolation Facility at the Churchill Hospital in Oxford, which is pivotal to delivering insulin producing cells for human transplant across the UK. Under Mike's leadership, DRWF went on to open affiliates in France, Germany, Sweden, Finland, and Norway. All of whom provide diabetes awareness, information and support to their respective diabetes communities, whilst providing essential research funding for young and established scientists pursuing innovative research studies. Our motivation is the ever-incre3sing and staggering global diabetes statistics and the belief that we must make a difference across nations. Mike was an adventurous world traveler and outdoor enthusiast and took great pride in hiking to the bottom of the Grand Canyon {and back to the top) six times. He was also an enthusiastic fisherman. He is survived by his beloved wife of 54 years, four children, and 14 grandchildren, who lovingly refer to him as "Big Mike" DRWF was incredibly lucky to have had such a passionate and committed professional steering the charity's vision, mission and values. Mike's energy was felt throughout DRWF with a strong relationship with the charity's Chief Executive and the wider team which was often fondly likened to that of a 'family'. Mike's passing is a big1055, but our commitmentto the diabetes community remain5 unwavering. We will continue to forge ahead with Mike's vision and dream of a cure, to imagine a day without diabetes. Our work, together, stays focused on keeping people with diabetes well until a cure is found and your support makes all the difference. Thank you! John Alahouzos March 2025 TRUSTEES ANNUAL REPORT FYE2024

Diabetes Re50arch Et Wellne55 Foundarion st Report of the trustees for the year ended 31 December 2024 The trustees are pleased to present their report and message from the Chairman together with audited financial Statements for the year ended 31 December 2024. The financial statements comply with the Charities Art 2011; the Companies Act 2006,. the Memorandum and Articles of Association and are prepared in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102 Charities SORP) (effective from 151 January 20151. Our purpose, aims and activities The objects of the charity are: To assist in the relief of persons with diabetes and any similar or related diseases or conditions To raise public awareness about diabetes and any similar or related diseases or conditions, their incidence, causes, treatment, avoidance, and relief The focus of our work Since our inception in 1998, the number of people diagnosed with diabetes has more than doubled, Whilst there have been some incredible advances in treatment and technology in more recent times, which improve quality of life and reduce the risk of complications, the number of people living with diabetes continues to rise at an alarming rate. There are more than 5 million people now living with diabetes in the UK with around 90% of this attributed to the rising tide of type 2 diabetes. The NHS has also identified as many a5 500,000 more people in England who are at increased risk of developing type 2 diabetes in a year. Early identification means that an earlier diagnosis can be made along with earlier support to prevent the condition progressing and reducing the associated risks of cardiovascular disease, kidney failure, lower limb amputation and sight loss. There has been significant investment by the NHS in programmes to tackle the rising tide of type 2 diabetes through the Healthier You NHS Diabetes Prevention Programme, structured education and digital self-management tools, as well as almost £15 million investment in the Type 2 Today programme which aims to support up to 140,000 young people aged 18-39 who are living with early onset type 2 diabetes. People with type I diabetes have seen significant milestones in the av3i13bility of flash glucose sensing as well as the NHS announcement of the nation31 rollout of hybrid closed loop systems However, both type l and type 2 diabetes are progressive conditions meaning that people living with either condition are constantly navigating the health challenges that diabetes presents whilst the research we fund seeks a cure. Our mission is to support people living with all types of diabetes by providing the ongoing information, education and peer support required to face the challenge5 of living with a long term, often complex, condition head on and lead the best qual ity of life possi ble. To that end, our work in 2024 focused on- Redefining our health care professional strategy to understand how we can best support diabetes and related healthcare professionals in delivering quality information and 5UPPOrt to the diabetes community TRUSTEES ANNUAL REPORT FYE2024

Diabetes Research Wellne55 Foundation Delivering a stand-out United Thmugh Diabetes event, a wonderful concept that brings the diabetes community together with healthcare professionals, public health officials, research teams, third sector organisations and industry partners. All of whom are invested and intent on creating a brighter future for people with diabetes. Raising visibility of DRWF through demonstrating the impactful research that we have funded. Developing meaningful partnerships with organisations working in diabetes and related health. Increasing our reach of the public with awareness raising materials on prevention of type 2 diabetes. Delivering Patient Information Forum (PIFI accredited health and social care resources through multiple channels, Diversifying our income generating activities alongside creating cost efficiencies- an ongoing process with a focus on navigating the continuing financial challenges that charities face whilst endeavouring to create Sustainable income streams and a charity that is fit for the future. Demonstrating public benefit The trustees confirm that they have referred to the general guidance set out by Charity Commission on public benefit, The trustees are satisfied that the Charity's activities meet the principles of public benefit, defined as providing an identifiable benefitls to the public, or section of the public, and know of no detriment or harm that may be caused because of these artivities, which are clearly set out throughout this report. We are committed to ensuring that the values of equality, diversity and inclusion are embedded respertfully into everything that we do. We endeavour to make the charitvs information, education and support services available to all. Volunteers As a small team delivering numerous activities, we rely on the support of volunteers who participate by helping with administrative tasks in our office; delivering diabetes awareness and information materials; undertake user involvement exercises to help steer and develop our programme activitie5- SUPPOrt our educational events and community fundraising programme or sit on one of our expert panels for research or information review. The number of volunteers fluctuates each year but is crucial to helping us spread the word about the work we do and to support local and national community initiatives. In addition to our Trustees, we have an Editorial Advisory Board and a Research Advisory Board. These are panels of diabetes clinicians and scientists. and other relevant professionals and lay people, all of whom offertheir time and expertise voluntarily to ensure that we meet the high standard5 required of us through our Association of Medical Research Charities IAMRCI membership and our commitment to producing clinically evidenced heatth and social care information in line with our PIF accreditation. We wholeheartedly thank all our volunteers for their time. expertise and commitrnent which helps us raise awareness to the charity, maximise income and maintain high standards of work. Measuring Impact We use a mixed methods approach to monitor and evaluate our activities to ensure that they remain true to purpose and achieve desired outcomes. Stakeholders and beneficiaries are involved in these evaluation proce55e5 to ensure the continued relevance, quality, accessibility, and effectiveness of activities. We also undertake independent evaluation with specialist partners for specific projects where impartial opinion and/or additional expertise is required. We keep people with diabetes at the heart of what we do. Beneficiaries and supporter5 are involved in numerous ways to ensure that our support and resources are relevant, accessible and meet needs, helping to steer our research priorities and programme activities. TRUSTEES ANNUAL REPOR T FYE2024

Diobetes Research Wellness Foundation Activities & Achievements in 2024 In the spirit of our strapline, 'stoying well until a cure isfound.-.' our work is focused on two clear strands: The delivery of awareness, information and support programmes And the funding of diabetes research Awareness, information & support INFORMATION REACH: A large percentage of existing supporters and beneficiaries engage through offline channels and whilst we aim to diversify our activities and reach of a wider demographic of the online diabetes community, it is also important to ensure that we continue to reach the older demographic with awarene55 and educational content. In 2024, we distributed 109,419 campaignsto existing supporters through direct mail and reached a further 142,510 prospective beneficiaries and supporters with new awarenes5 campaigns, a 13.5Yo increase in volume on 2023. These appeals are dual purpose raising awareness and providing information about the charity's activities and funding, whilst seeking financial support. They also act as a stewardship tool, helping us to stay connected with long-standing supporter5 of the charity. Each campaign provides health infomiation targeted at beneficiaries who could act on the information, either in a preventative way (type 2 diabetes), or to inform and support those living with diabetes (all types), in their self-management of the condition. We had an average campaign response rate of 12.5¥0 across 2 streams resulting in over 30,496 responses from across the country. We know from experience that it is likely that many more opened and read the appeal but chose not to make direct contact with us at that time. Historically, we have seen numbers of people respond to communications that have been distributed many month5, or even years, before as they have held onto the information provided for future reference, WEBSITE: Total number of visits to our website in 2024 was 311,000, up 13% from 275,000 in 2023. Active users {unique) visiting the site was 185,000, up 35% on 2023. Our United Through Diabetes Digital Hub roceived 9619 views from 6716 active users. Engagement on our website, such as likes, downloads. video views or link clicks, reached I million in 2024 which is an increase of 23% on 2023. PATIENT INFORMATION FORUM {PiF) TICK: As members of the Patient Information Forum, we hold PIF Tick accreditation on our adult health and social care resources. The PIF Tick kite mark is displayed on our information resources. This demonstrates that we are a 'trusted information creator, which is an important way in which people seeking our help can recognise that our information is relevant, up-to-date, clinically referenced and peer reviewed. INFORMATION/ACCESSIBILITY: There were 10,972 pdf downloads from our website in 2024, 82(/Fo of which were copies of our diabetes information leaflets. Additionally, there were also 221 audio downloads of these resources. Further, there were 316 '1istens' to our Living with Diabetes podcast sessions, a channel that we are working hard to develop. We increased the volume of video content available to visitors in 2024 to ensure choice of channel and accessibility of our information. There were 1936 video views in the year. the majority of which was related to educational content via our UTD Digital Hub. SOCIAL MEDIA CHANNELS: Social media channels are a great way to reach a wider audience, quickly, with messages about our activities. Whilst we use multiple social media channels, we get greatest engagement in posts about our community activities via Facebook. Our Facebook reach in 2024 was 2.6 million an increase of 25.8% on reach in 2023. TRUSTEES ANNUAL REPORT FYE2024

Diabetés Research Et Wellness Foundation DIABEfES WELLNESS NEfwoRK: The network is a core group of subscribers who receive a quarterly edition of the Diabetes Wellness News. These are predominantly people with type l ar)d type 2 diabetes and health care professior)als wor*ing in diabetes and related health. In 2024, we circulated 25685 copies of the Diabetes Wellness News which 15 a 16-page magazine containing specially commissioned articles on all aspects of diabetes self-management, as well as advances in research and general diabetes news. Diabetes Wellness Events- Qic award winning educational events: Self-management is the cornerstone of diabetes care, with good self- management skills essential to achieve positive health outcomes and reduce the risk of associated health complications. Qic For the past 25 years, DRWF has been providing an annual programme of Diabetes Wellness events that are focused on enabling people to access relevant, evidence-based health information throughout the lifetime of their long-term condition. Whilst providing a wide range of diabetes and related-health workshops, interactive sessions and talks, the core principle on which this programme is built is 'peer support., Peer support is a valuable resource for people living with diabetes, their family, friends and carers and our Wellness events provide an opportunity to make new contacts and build new relationships through mutual acceptance and understanding, in 3 safe and inclusive environment. Our events inform, inspire and empower people to take ownership of and have more control over their health and wellbeing. The diverse learning programme on offer helps people to develop knowledge, skills and confidence to address issues that are affecting their health and diabetes self-management. This is especially beneficial to people who are lonely or isolated and don't have an immediate support network around them. We believe that this holistic approach supports all round wellbeing and increases learning capacity and resilience, and it is wonderful to see people return to our events year-on-year. United Through Diabetes- the BIG Diabetes Wellness Day 395 On Saturday 215t September. we hosted the second United Thmugh Diabetes in- person event which saw 395 delegates in attendance. The event was supported by Industry partners, and prominent speakers, such as the National Specialty Advisory for Diabetes {NHS England), Profe550r Partha Kar. The event reached a wide and diverse segment of the diabetes community, including families of children with type I diabetes, people with type I, type 2 and other types of diabetes, as well as people working in diabetes and related healthcare. Attendees were able to engage with DRWF funded researchers, past and present, to understand how the work we have invested in over the past 26 years has delivered impact/benefit for people with diabetes. Feedback on the quality and variety of workshops and talks on offer was extremely positive and the UTD Digital Hub extended our reach post-event to enable people who couldn't attend the event in-person to benefit from the programme content. TRUSTEES ANNUAL REPORT FYE2024

Diabètes ResEarch Wèllness Fo￿ndation Numerous organisations supported the delFveryof the event as well as providing funding for filming of the research panel session, all of whom were appropriately acknowledged on the DRWF Digital Hub. Diabetes Wellness Family Camp 75 Family Camp took place 10- th 12 May at Whitemoor Lakes in St3ffordshire. We received 35 family applications {138 individuals). Our aim was to accommodate 20 fa m ilies {70 individuals). Following triage and withdrawals we accommodated 19 familiesl75 individuals. There is a robust triage process in place for Family Camp given that many children are living with complex health needs beyond type I diabetes. We would like to say what an amazing weekend we all had at camp last weekll Our daughter wanted to come to meet other young people her age with type I diabetes which she didll Numbers & snaps exchanged. The cump was absolutely fantastic & fvn for all thefamily.111 Our daughter has begged us to apply to come back again for next time/next year. Camp & theformat wos great & very well balanced. All those that did not meet the criteria for Family Camp were offered places at our Autumn virtual Camp in the Cloud. The aim of Camp is to bring families of children with Type I diabetes together in a fun, safe and welcoming environment. The emphasis is on providinE fun for the children and a little respite for the parents/guardians and perhaps most importantly, providing a platform for meeting families to share similar experiences of life with diabetes so as to build relationships based on mutual understanding and acceptance. There was a full programme of activity for the families to enjoy over the duration of the weekend with a diet and nutrition talk from Lisa Poole, HCPC registered dietitian with specialist experience in working with children. 26 Virtual Camp in the Cloud Virtual Camp in the Cloud was introduced during the pandemic period when in-person activities were curtailed. Due to its ease of access. we have continued to offer this fun, online 'Camp' in addition to our residential activity in the year. An opportunity to experience something fun that's related to my child s diagnosis, feeling special. having a unique day we've never had before.- Seeing otherfamilies on the call. How warm t7nd engaging the staff were. That my little warriorfelt so appreciated sporting his t-shirt, hoving his face painting and building stronger bonds with his sister. A full programme of online activities wasoffered, with a box of arts and crafts, and other materiaSs, supplied beforehand to make the day as interactive and fun as possible. DRWF hosted a Talking Typel, session for the parents/guardi3ns where they could raise important questions and share their experiences with each other in a safe and inclusive space. TRUSTEES ANNUAL REPORT FYE2024

(;) Diabetes Resèarth tr Wellnes5 Foundation Feelings before attending Camp in the Cloud ... Bottled-up Winlery Disengagecl Gratef Ul LOW Blue Apprehensive Feelings after attending Camp in the Cloud ... Technophofjic Interested Calm Connected TxreiJ Diabetes Wellness Morning- Hartlepool The Diabetes Wellness Morning in Hartlepool wa5 hosted on behalf of DRWF by longtime volunteer, Hayley Hakansson. and coincided with World Diabetes Day. The event was held at the National Museum of the Royal Navy and was attended by 81 people. The aim of the morning was to support people living with diabetes, their family. and carer5, to provide practical information, tools and tips to improve self-management and understanding of the condition whilst providing an opportunity to spend time with diabetes healthcare professionals. The event was organised with the support of the Hartlepool Diabete5 Support Group and colleagues at the North Tees and Hartlepool NHS Foundation Trust. Attendees enjoyed a busy morning featuring talks and presentations on all aspects of diabetes and related health. Peer support is at the core of this event which provides the opportunity to meet new people living with diabetes in the local area whilst refreshing existing knowledge and learning new ways in which to optimise self-management. Hayley said: Everyone attending the event said how warm and welcoming the Wellness Morning was and they felt they had learned sornething new, in additiorb to refreshing their knowledge of helpful tIP5 for living with diabetes." TRUSTEES ANNUAL REPORT FYE2024

OièbÈtes Researth & Wellness Foundation ROTr AI_ S()Cl F_-I')' 1>1 MEDI("IN'L Royal Society of Medicine- Medicine & Me Partnership th On Monday 30 Septernber, DRWF partnered with the Royal Society of Medicine to deliver an online event for healthcare professionals and people living with diabetes. Under the banner of 'Engaging Communities- tackling health Inequolitie5 in dlobetes,, the event explored 3 key areas, environmental, cultura l and language. With a platform for sharing experience. we hoped to develop our understanding of how stigma, socio economic factors and inequalities in healthcare can impact on the lives of people with diabetes, helping us to consider the barriers and challenges to effective community engagement. The Welcome address was given by Sarah Tutton, Chief Executive of DRWF with Sanjay Gohil as Chair. Speakers were Dr Sue Jones, Consultant Diabetologist {Newc3stle); Dr Faye Ruddock, Chair of the Caribbean and African Health Network (CAHNI; Dr Mayank Patel, Consultant in adult diabetes {Southampton). There were 222 event registrations with around 30% attrition on the day. This is typical of an online event, particularly where healthcare professionals are registering their space to participate on and around their working day. The event ran between 12 noon and 3.30pm to cover the lunchtime period with a couple of short comfort breaks. Post-event feedback was very good with some very encouraging comments about the speakers and subject matter. Just over 93% of survey respondents said that the subject matter/content was good-very good with 85% saying that they would recommend to a colleague. Importantly, 82% of healthcare professional attendees said that the information gleaned during the webinar would positively impact on their clinical practice. Research Funding Programme Each year, we issue Calls for Applications in respect of our3-year Clinical, Non-clinical and Pump Priming awards. DRWF Fellowships provide the necessary funding to support Early Career Researchers IECR) which is vita I ly im portant to ensure that clinica l and scientific talent stays a nd develops within the diabetes medical research community. ECR'S represent a young and diverse research population. and provide a constant flow of talent, new ideas and new skills. Some of them will go on to be the senior diabetes researchers of the future, so with very few funding awards available to this vital community, the DRWF awards are lucrative and well positioned to attract the best and brightest young researchers. Our Pump Prirning stream is a proof-of concept funding channel, which aim5 to produce translational pilot study data that goes on to leverage higher value, longer term funding from other organisations to take the research conducted to the next level. The DRWF annual funding round is offered through open competition, and as such, enables funded researchers to access support for both direct and indirect costs of research via the Charity Research Support Fund (CRSF) and NIHR Clinical Research Networks ACORD ag￿eMent. Institutional and discretionary awards are available when funds allow. Contract funding of key personnel within the DRWF Human Islet Isolation Facility at the Churchill Hospital, OxFord is subject to proposal and reviewed on a multi- year rolling contract basis. Central to this review, is the continuation of the facility's Plvotal role in the UK Islet Transplant Programme and ongoing NHS clinical funding availability/plants for future years. TRUSTEES ANNUAL REPORT FYE2024

Dièbetes Research Er Wellness Foundation DRWF is a member of the Association of Medical Research Charities {AMRC). a membership body representing the leading medic31 and health research charities who deliver high-quality research that save5 and improves lives. Working with member charities and partners, AMRC aims to support voluntary sector effectiveness and advance medical research by developing best practice, providing information and guidance, improving public dialogue about research and science, and influenclng govemment. As a member, we subscribe to AMRCS criteria forthe use of peer review for allocating funding and support AMRC position statements on the payment of indirect costsin universities and the use of animals in medical research which seeks to replace, refine and reduce the use of animals {3Rs) in research. We operate a rigorous peer review prO￿5S by which our Research Advisory Board {RABI, clinical and scientific experts in the field of diabetes and related health, assess applications and reports to ensure that only the highest quality and most effective research, carried out using good or best practice methodologies, receives DRWF funding. Pump Priming Awards Diabetes Research Weiiness Foundatlon Research Strategy 2024-26 Calls for applications were issued in September 2023 for Pump Priming Awards to be taken up in 2024. A total of 20 appllcations were received from which six research awards were made wrth a total value of £119.982. The DRWF research programme is designed to support bright young researchers, as well as established institLrtions, asthey strNe to make the kind of life-changing breakthrough our diabetes community is hoping for. Pump Priming awards considered 'proof of concept, and are either Clinical or Non-clinical in nature. Successful projects are funded for up totwo year's duration, to the value of £20,000. No-c05t extensions to the term may be considered. RESEARCH Islet Cell Research & Transplant DRWF has made a considerable contribution to the funding of islet cell research and transplant in the UK and around the world. The DRWF Human Islet Isolation Facility at Churchill Hospital, Oxford plays a pivotal role in providing islets for research and transplant as part of a national treatment programme, the clinical element of which is funded by the NHS. UNIVERSITY OF OXFORD Three personnel are funded within the facility (around 30% of facility staffl.. Lab Manager Deputy Facility Manager {post doc researcher) Islet Transplant Administrator We maintained our contract funding awards at the DRWF Islet Isolation Facility, Churchill Hospital, Oxford. These posts are funded for between 3-5 years, giving continuity and stability to the individual post holders and wider facility/teams. This is vitally important to ensure sustainability of expertise within the research group, given that this faci lity works on rotation to isolate islet cells for human transplant, as well as Supply islets for research across the UK and Europe. 10 TRUSTEES ANNUAL REPORT FYE2024

Diabetes Research & Wellness FoundatTon Impact report from the Director of the DRWF Islet Isolation Facility Churchill Hospital, Oxford by Professor Paul Johnson Introduction 2024 was the 18th year since the opening of the DRWF Oxford Human Islet Isolation Facility. It continues to be one of the key islet isolation facilities in Europe providing clinical islets for both allo- and auto-transplantation, as well as distributing research islet5 for a network of basic and clinical researchers around the UK. It also continues to be active in research and development in the fields of islet isolation and islet transplantation. This report Elves a brief overview of the main areas of activity during 2024. Islet Allo-transplantation Our allo-isolation programme had a successful year overall. We continued to provide human islets for the UK Islet Transplant Consortium, maintaining the clinical service despite our partner isolation facility at King5 in London having to close between June 2023 and October 2024 due to a contamination issue. This unexpected and prolonged closure increased the pressure on the Oxford and Edinburgh Islet Isolation Facilities, but between January 2024 and December 2024, the DRWF Oxford Islet Isolation Facility performed 22 clinical islet isolations for allogenic use, 9 of which metthe UK agreed release criteria for transplantation. This is a conversion rate of 41% (international average conversion is about 30%). On the clinical side, the Oxford programme continued to cover a wide catchment area in the UK and the satellite clinics in Birmingham and Leicester continued to be fruitful, offering a quaternary service closerto the patients, homes. We continued to champion a patient-centric integrated beta-cell replacement model, and because of this our Simultaneous Islet Kidney {SIK} and Islet After Kidney {IAK) transplant referrals increased considerably and these now reflect on our islet transplant waiting list. Indeed, with the routine use of closed loop insulin delivery, the previous primary indication of life-threatening hypoglycaemia is becoming a much less common i ndication for islet transplantation worldwide. Islet Auto-transplantation Our NHS-commissioned programme for total pancreatectomy with islet auto-transplantation ITPIATI for chronic pancreatitis, continued to thrive with increasing referral numbers and excellent outcomes. In 2024, the DRWF Islet Isolation Facility performed 8 clinical islet isolations for autologous use. 7 of these 8 preparation5 were transplanted. We have now undertaken 3 TPIATS in the under 18 age group and our paediatric referra15 for TPIAT are increa5inE. As a result, we have applied for NHS-commissioning to be able to routinely undertake TPIAT in children, something that we believe our expertise in Oxford makes us ideally placed to do. Ultimately, we hope that this will be the next step to our long-term goal of performing islet transplantation in children with type I diabetes soon after diagnosis. Research Islet Provision The DRWF Isolation Facility in Oxford continues to be the UK Islet Resource Centre providing human islets for research to a network of type l and type 2 diabetes researchers. In 2024, our team distributed 1.8 million islet equivalents (IEQ - the i nternational standardised way of counting i51ets) from 8 islet preparation5. In addition, the Oxford DRWF Islet Isolation team continued to lead the 'lslet Platform, for the related Quality in Organ Donation IQUOD} with responsibility for isolating and distributing islets for research from these rare pancreases. We are also part of two collaborative research projects under the Diabetes UK Type l Diabetes Grand Challenge, something that we believe is of enormous benefit to DRWF within the current landscape of diabetes research in the UK. Vertex Stem-cell Derlved Islet Trials As stated in last yearfs report, in 2023, Oxford was opened as the first site in the UK (and one of only a handful in Europe) for the Vertex 880 and Vertex 264 stem-cell derived islet transplant trials. We continued to actively recruit for these studies. The publicly available international data for the VX 880 trial is looking very encouraging. The fact 11 TRUSTEES ANNUAL REPORT FYE2024

Diabetes Research Wellness FoundatTon that the Oxford DRWF Isolation Facility team are playing such a key role in these landmark studies again demonstrates the wider impact that DRWF are having in the islet transplant field internationally. DRWF Islet Facillty Staff Our DRWF-funded staff - Rebecca Spiers, Louise Stile. and Ahmad Kobiita - continued to be key to the day to day running of the Islet Facility and the Islet Isolation Programme. Indeed, I remain extremely grateful to each one of them for their essential contributions. Biennial HTA Inspertion and Licenslng In July 2024, we underwent our biennial rigorous inspection from the Human Tissue Authority. Rebecca Spiers and the team Spent hours preparing all the documentation and data for this. The inspection went well, and we were delighted to receive our most successful inspection report yet. This is testimony to the meticulous regulatory management of Rebecca, and the hard work and cohesion of the whole isolation team. Finally, I would like to once again reiterate my immense gratitude to DRWF for their ongoing generosity in funding the Oxford Programme, and to reiterate my team's total commitment to maintaining our close and successful partnership with DRWF for many years to come. We are a150 committed to continuing to champion the wonderful work of DRWF in every way we can. Professor Paul Johnson Professor of Paediatric Surgeryj University of Oxford Director of the Oxford Islet Transplant Program & DRWF Human Islet Isolation Facility Research impact Each year, our funded researchers deliver interim and annual reports to demonstrate that their work aligns with the award criteria and progress updates are provided throughout the term of funding. These reports are reviewed by the Research Advisory Board, from which we publish articles in our quarterly Diabete5 Wellness News to update our beneficiaries and supporters on the impact that our funding is having for people with diabetes. Here ore two such exomples published in 2024- Unravelling the mystery of diabetic pain An exciting breakthrough in neuropathy research Introduction to the Pioneeri ng Research In the quest to enhance the quality of life for millions affected by diabetes, a recent study sponsored by the Diabetes Research and Wellness Foundation has delivered groundbreaking insights into the mechanisms of diabetic neuropathic pain. This extensive investigation, led by Dr Richard Hulse at Nottingham Trent University, not only deepens our understanding of a prevalent complication associated with diabetes but also opens the door to potentially revolutionary treatments. By exploring the underlying causes of neuropathic pain, which many patients experience as debilitating and persistent discomfort, the research holds the promise of developing therapeutic strategies that could significantly alleviate, or even completely eradicate, this often-intractable pain. The significance of this research lies in its potential to transform the current approach to diabetes management. Neuropathic pain can severely impact an individual'sfunctionality and overall well-being, making everyday activities challengingand diminishing life quality. This detailed study could pave the wayfor innovative treatments thattarget the root Causes of neuropathic pain rather than merely managing symptoms. 12 TRUSTEES ANNUAL REPORT FYE2024

Diabete5 Research EF Wellne55 Fovndaiion Such advancements might not only improve care outcomes but also reduce the long-temi economic costs on healthcare systems caused by chronic pain management in diabetic patients. By providing a new pathway for treatment, the findings from this study are a beacon of hope for those who suffer from the continuous struggle ag3inst diabetic pain. What is Diabetic Neuropathic Pain? Diabetic neuropathy, or neuropathic pain, is a common and often severe complication of diabetes. The pain experienced can vary widely in nature but Is often described as burning, stabbing, or throbbing. Imagine a constant ache that not only disrupts your daily activities but also interferes with your sleep, making even light touches feel painfully intense. Neuropathic pain can severely diminish quality of life, afferting both physical and mental health. Ivs a persistent reminder of the underlying condition-diabetes that requires careful management and treatment. Understanding and addressing thi5 type of pain is crucial for improving overall well-being and maintaining an active, fulfilling life despite having diabetes. Traditionally, this pain was thought to stem from nerve damage caused by high blood sugar levels. However, the recent study suggests a different cause: reduced blood flow to the spinal cord, leading to oxygen-deprived neurons in the dorsal horn of the spine. Explorin8 the Role of Hypoxla-lnducible Fartor l Alpha IHIFla) At the heart of the study is a protein known as Hypoxia-lnducible Factor l Alpha IHIFlal, which significantly influences how cells adapt to conditions of low oxygen, a common issue in areas of the body with poor blood circulation like the spinal cord in people with diabetes. The researchers concentrated their efforts on decoding how HIFla modifies pain perception particularly under diabetic conditions that typically exacerbate such complications. By employing advanced genetic engineering techniques, the team specifically targeted and deleted the HIFlct gene from certain neurons in the spinal cord of mice. This precise modification allowed them to obsenie the role of this protein in neuropathic pain pathways more clearly. Through this approach, they hoped to uncover whether reducing HIFla leve15 in specific neural populations could alleviate pain, thereby providing a potential new therapeutic avenue for treating chronic pain in diabetic patients. This exploration 15 crucial for developing targeted treatments that address the underlying causes of neuropathic pain without the side effects associated with less specific pain relief methods. Innovative Research Methods The scientific team utilized several advanced, cutting-edge techniques to conduct their research.. Genetic Modifications: Using a specialised virus, they were able to specific311y delete the HIFla gene in targeted neurons, observing how this genetic alteration affected diabetic pain. Behavioural Assays: These tests were crucial for evaluating the pain response in genetically modified mice, helping to establish a behavioural baseline and assess the effectiveness of the genetic modifications. Proteomic and Histological Analysis: By analysing proteins and cellular structures in the spinal cord, researchers could identify changes associated with pain pathways, providing a deeper understanding of the underlying mechanisms. 13 TRUSTEES ANNUAL REPORT FYE2024

Diabete5 Research ty Wellness Foundation Key Findings: A Link Between Hypoxia and Pain The experiments provided illuminating results. showing that hypoxia a state of low oxygen levels in the tissues- in spinal neurons could directly initiate the experience of pain sensations. The scientists discovered that bv strategically blocking the actlvlty of HIFla, they could effectively prevent the onset of neuropathic pain in the spinal cords of their diabetic mouse models. This critical finding suggests that the HIFla pathway plays a significant role in mediating pain, and that inhibiting this pathway could significantly reduce or even eliminate neuropathic pain in patients with diabetes. Why This Is Important This research offers hope for better pain management in diabetes. By potentially eliminating a root cause of neuropathic pain, future treatments could lessen the reliance on traditional painkillers, which often come with side effects and limited efficacy in chronic conditions. If these findings can be translated into human treatments, it could mean: Enhanced Pain Management: More effective treatments could directly reduce the frequency and severity of neuropathic pain episodes. Improved Overall Well-belng: Effective pain relief significantly contributes to better mobility, mood, and quality of life. Looking ahead, the research team at Nottingham Trent University are excited to further explore this promising avenue. with further studies aimed at understanding and eventually interruptingthe pain signals caused by hypoxia in patients with diabetes. The a im is to translate these findings into therapies that can be tested in clinical settings. Concluslon: Towards a Pain-Free Future This promising research offers more than just insights-it provides hope. As scientists continue to decode the complexity of diabetic pain, their findings could lead to revolutionary treatments. The journey from bench to bedside is long and complex, but the potential to improve the lives of those with diabetes is a powerful motivator. In summary, the dedication of researchers at Nottingham Trent University, coupled with innovative genetic and molecular techniques, is settingthe stage for significant advancements in the treatment of diabetic neuropathy. By directly targeting the newly uncovered mechanisms of disease, they are not only shedding light on previously obscure aspects of diabetic pain but also working towards a future where diabetes can be managed without pain. Praising the quality of the study, DRWF Research Advisory Board member, Professor Ketan Dhatariya recognises that it's challenging the prevailing understanding of neuropathic pain as being caused by nerve damage from high blood sugar levels. The diabetes consultant and current chair of the Association of British Clinical Diabetologists sa id This is the first step to developin9 new mode15 of pain. As the research team stote, the next Step 15 to develop HIF knockout mice to determine of their hypothesis (Ind preliminary results are correct. If they are, then the next step would be to investigate potential agents to do the some and ultimately to develop therapeutic agents to treat diabetic neuropothic pain. He adds "Congratulotions on the work, I think this is an understudied area 14 TRUSTEES ANNUAL REPORT FYE2024

Diabetes fte5e3rch £* Wellness Foun¢Jaiion Unlocking Hope: Enhancing Islet Transplantation for Type l Diabetes Revolutionising treatment through Msc-secreted molecules A groundbreaking study, funded by the Diabetes Research & Wellness Foundation, could significantly enhance the INes of those suffering from type I diabete5. Scientists in London and Exeter have discovered a method to improve the survival and function of transplanted islet cells, the insulin-producing cells often lost in this condition. Type I diabetes is a challenging illness where the body's immune system mistakenly attacks these vital cells, leading to a dependency on insulin injections. Islet transplantation offers a beacon of hope for patients, yet its effectiveness is hampered by the rapid loss of transplanted i51et cells shortly after the procedure. This new research, however, shines a light on a promising solution. Exploring the Healing Potential of Mesenchymal Stromal Cells At the core of this scientific breakthrough are mesenchymal stromal cells {MSCsl, which are known for their tissue- repairing abilities. These cells secrete a range of molecules that have been found to significantly enhance the survival and function of transplanted islet cells in mouse models. The researchers set their sights on whether this success could be replicated with human islet cells, using a meticulously crafted cocktail of Msc-secreted peptides. Enhancing151et Survlval and Function Through MSC-Secreted Molecules The study involved treating human islet cells, SOLJrced from nine donors, with this special cocktail before transplanting them into diabetic mice. The results were compelling. Not only did the pre-treated islet cells demonstrate an improved ability to produce insulin in response to glucose, but they also showed a remarkable resistance to apoptosis, a form of programmed cell death induced by inflamrnatory cytokines, which are often present in high levels in transplant environments. What stands out in thi5 research is not just the in vitro success but also the remarkable in vivo outcomes. Diabetic mice that received the MSC-treated human islet transplants maintained normal blood glucose leve15 for an extended period, highlighting the enhanced survival and functional capability of the treated islets. This was in stark contrast to mice that did not receive transplants and suffered from elevated blood glucose levels. Expandlng the Posslbilltles of Islet Transplantation for Type l Diabetes The study underscore5 the potential of using a defined cocktail of Msc-secreted molecules to precondition human islet cells before transplantation. This approach could significantly improve the longevity and efficacy of islet transplants, offering a more durable solution for managing type I diabetes. By increasing the functional survival of transplanted islets, this method could potentially expand the pool of viable i51et donors, making the treatment accessible to a broader range of patients. The implications of this research are profound. By addressing one of the critical challenges in islet transplantation the rapid loss of transplanted cells this approach paves the way for more successful diabete5 treatments. It not only promises to enhance the quality of life forthose living with type I diabetes but also signifies a step forward in the quest for a cure. In essence, this study illuminates a path toward improving the outcomes of human islet transplantation through a novel, cell-free strategy. By leveraging the healing powers of Msc-secreted molecules, scientists are on the brink of making islet transplantation a more effective, reliable treatment for type I diabetes. This research not only highlights the innovative intersections of cellular biology and medical treatment but also Dffers hope for a future where managing diabetes could be less about daily struggles and more about long-term recovery. 15 TRUSTEES ANNUAL REPORT FYE2024

Dlabeies Research F* Wetlness Foundation Global consen5US Statement endorsement In 2023, we were asked to endorse a Global Consensus Statement Towards standordizrrtion of person-reported outcomes IPRO'SJ in diobetes research. This project was to address the lack of standardization/harmoniz3tion of PRO'S (person reported outcomes), limiting the comparability of findings acros5 Studie5 in a space where too often, patient's perspectives of their lived experience with diabetes are lacking as primary or even secondary outcomes in clinical trials. We considered this to be an interesting and important piece of work given that clinical outcomes in diabetes are intimately tied to how the person living with diabetes reacts to and implements treatment recommendations. It was on this basis that DRWF endorsed the global consensus statement project. This global endeavour resulted in two final manuscripts, for adult and paediatric care, being delivered for publication in March and July, respectively in Diabetic Medicine and Behavioral Diabetes Institute. Fundraising Policy: The Trustees are aware of their responsibility and accountsbility to ensure that the charity fundraises legally, responsibly, and effectively. Our plan for 2024 was to maintain focus on building resilience and sustainability for the future through succession planning, diversification of income streams and delivery of purposeful programs that continue to meet the ever- changing needs of people with dlabetes. Corporate Partnerships: We do not endorse products, but we will support initiatives that increase awareness to DRWF and our activities, and where there is an appropriate message, product, or service for people with diabetes. To this end, we have explored meaningful partnership and corporate sponsorship opportunities, where there is a synergy in mission, vision, and values. Any potential partnership is assessed for feasibility, compatibility with our own objectives, and risk to ensure there is no detrimental effect to our reputation, fundraising Potential or the audiences that we exist to serve. Robust risk assessment supports our desire to only engage in suitable and best value partnerships. Detailed discussion and negotiation ensure that the aims of both parties are complementary and mutually beneficial and in line with any regulatory/industry standards. This maintains transparency and integrity in all partnerships. Professional Fundraisers: Whilst we use the services of fundraising consultants. as and when needed, to advise on some of our activities, we did not work with a professional fundraiser during the year. Commercial participation agreement5 are in place where necessary. YOU make ALL the difference! As a charity that exists almost entirely. at this time, on voluntary donations and fundraised income, we are always humbled and heartened by the support that we receive. Here 15 3 snapshot of some of the community activities that took place in 2024 that helped raise awarenes5 of diabetes, the charity and its services, as well as vitsl funds to support all our charitable activitie5- 16 TRUSTEES ANNUAL REPORT FYE2024

Diabete5 Reseaith Et Welipess Foundation TCS London Marathon 2024 We were very lucky to receive 8 gifted places in the 2024 London Marathon from a corporate partner. This enabled us to issue a call for applications. Following a thorough review process, the places were allocated to 8 amazing runners who raised over £25,619 for DRWF. rth ..fidJ 7nRa2 LONDON MARATHON OUR CLASS OF 2024 20422 r(hts "My journey with diabetes hos inspired me to join the mortithon teom ond rtlise fundsfor the Diabetes Research & Wellness Foundation. Since my diagnosis in 2018, I've been enthused by efforts to odvonce care andfind u curefor this condition. Whot drives me even more is the stigma GSSOCI(7ted with diabetes, fuelled by o lack of understanding ond misconceptions in society. I've encountered ignorance and negativity, which only emphasise the urgent needfor education and increased awareness. Whilst oiming to achieve a great time, J also wanedt to challenge this stigma in the process. I believe that with increused understanding, we can change perceptions und support other5 affected by diabetes." Lyle Pentith- DRWF London Marathon 2024. 17 TRUSTEES ANNUAL REPORT FYE2024

Diabete5 Re5earth Wellness Foundatlon Dance for Diabetes Dance for Diabetes saw impressive grovrth in 2024. We connected with more families and made a bigger Impatt through educational resources, school assemblies, and fundraising incentives. Fifteen schools across Hampshire took part, with 4,431 children raising an incredible £27,629. This was a 56°A increase in funds compared to 2023 and 3 64% rise in the number of participants. Since 2022, we've given back over £20,000 to the schools involved in the program, thanks to our commitment to share 40p of every £1 raised at each school. This support has helped schools purchase items like playground benches, sensory gardens, outdoor equipment, and musical instruments. Looking ahead, we aim to expand this event in 2025 with a goal of reaching 5,000 students and raising an ambitious £35,000. This model demonstrates a community partnership that benefits everyone involved, raising awareness of diabetes amongst schools, families and children through our healthy lunchbox literature whilst raising income that is split 60% to DRWF and 40% to participating schools. New Horizon5 Primary School relished the opportunity to be involved with Dancefor Diabetes. Combining the Jearning of this darjce within PE lessons ond children proctising at home, it was (7 fL7ntastic way to encourage children to get moving in u fun environment. The atmosphere in school was incredible, we ran the event os o multi-coloured dress down day ond we decorated the playgrounds with multicolour bunting so there really was a party atmosphere. Not only did Gll our children love being involved in the event, but It also meant as a school we generated an income of £1, 785.96 (40Y) which was on amazing result . Mr Jones Headteacher, New Horlzons Primary School Thinking Schools Academy Trust. . 5£a 1.645-, hauls Iw pori £7.762 OUR %-IOR& so fAR 2022 15 4,431 Sch00I5 pv￿15 taok ￿rt W r￿Se￿.. £27.629 2023 10&¢ti 2,839 I￿• w•talt4d..£15,439 29tt, 0¥orQC.OOQ W¢ ltyvt tor ￿￿￿515 lo lu&t port 2025 £35,000! 1;.,,: rog4R¥••POF 18 TRUSTEES ANNUAL REPORT FYE2024

Diabetes Research f* Wellness Foundation •• TRUSTEES ANNUAL REPORT FYE2024

Diabètss Research E Wellness Fovndat?on Cardiff half-marathon 2024 We managed to secure 15 spots for the 2024 Cardiff Half Marathon and to our amazement, the event sold out to the public in no time which helped us to quickly allocate our own places. Before long, we were collaborating with an amazing group of enthusiastic and dedicated runners. Thanks to their efforts we exceeded our initial fundraising goal raising an impressive £8,303.75. res Re Inew Fou "In September Just year I st7dly lost a specialfamily member. A man thot I wos proud to call my grondfother. For the majority of his life, he suffered with ill health mainly caused by Diabetes. Wotching him bottle through all that he did with no fear or complaints has made me reali5e what a truefighter meant in my eyes. He was a kind, loving ond u very hardworking man th(7t would olways prioritise others. even if his health hod the best of him some days. He loved being in hi5 fomily's company that he cherished and odored dearly. Watching him succeed in life has taught me thot hord work does pay offl Therefore. in memory of his life, I decided to porticipote in running the Cardiff Half Marathon in 2024 with o torget of supportin9 011 that are living with Diobetes." Maddison Rae Evans- Cardiff Half Marathon 2024. 20 TRUSTEES ANNUAL REPORT FYE2024

Diabetes ReseaTch Weline55 Foundation Fundraising Regulator We are a levy-paying member of the Fundraising Regulator and subscribe to the associated fundraising codes of practice. The charity suppresses individual supporter records against the Mailing Preference Service, Telephone Preference Service, and the Fundraising Preference Service, which helps to ensure that we do not approach individuals who have expressly requested that we do not contact them. During the year, we were notified of 9 FPS requests, which were suppressed from all contact, this is SO% lower than the 18 received in 2023. Complaints The charity has a published complaints procedure, available on its website. and endeavours to respond to enquiries and complaints within the stated timeframe. Most contscts tend to be a request to opt-out of charity communications by existing supporters and we monitor the basi5 on which people request this i.e., content of appeal, volume of contact; type of contact; method of contact to inform our campaigns Wlth the aim of reducing any perception of unreasonable intrusion. persistent approach or undue pressure to support. We didn't receive any complaints about our fundraising practices during the year. GDPR and Data Protection We are committed to protecting the personal information and privary of individua15 that we engage with and comply with relevant legislation and codes of practice, whilst carrying out our essential work of raising awareness of diabetes, providing information and support, and raising funds. Our privacy policy, published at drwf.org.uk sets out how we capture, process, manage and retain personal information. Financial Review Principal incame streams in the year were direct mail campaigns; regular giving via direct debit; legacy income and gift aid associated with voluntary donations. Income= Total income was £1,534,027. This wa5 10% below budgeted income (£1,701,396) and 7.5Yo less than income received in 20231£1,658,853). Voluntary donations including gift aid receipts at £637,145 were 18% less than income received in 20231£777,9321. Legacy, In Memory & Trust income was £628.727 which was 20go higher than received in 20231£524,625), as expected given the volume and value of legacies received and accounted for in the previous year. Expendlture: Total expenditure was £1,792,042 which was 6% below budget (£1,904,223), and 3Yo less than expenditure in 2023 (£1,855,067). At year-end we had a deficit of £258,015. This was 27% more than we had anticipated when budgeting for the year where we had predicted a deficit of £202,827. Whilst expenditure in the year was under budget, the deficit was impacted quite significantly by the reduction in voluntary donations and fijndraised income received in the year. Direct charitable expenditure was 85p for every £1 Spent (80p in 20231. We believe this demonstrates our cornmitmentto spending income on delivering the services for which we exist to provide. Government Grants The charity received £131,578 from the Government's Covid Medical Research Charity Support Fund {BEIS) to support existing funding commitments of identified early career researchers. 21 TRUSTEES ANNUAL REPORT FYE2024

D¥èbete5 Researih tr Wellness Foundation Investment Policy Under the Memorandum and Articles of Association, the charity has the power to invest in any way the trustees see fit. The trustees are aware and mindful of the Charity Commission CC14 guidance on investments. The trustees, to minimi5e risk and having regard to the liquidity requirements of the charity, and to the reserves policy, have historically operated a policy of keeping available funds in a higher interest-bearing deposit account seeking to achieve a rate of deposit interest which matches or exceeds inflation as measured by the retail prices index. The trustees have regularly reviewed opportunities to increase investment return from short-term, easy access, options bearing in mind the desire to ensure that we can react quickly to appropriate requests for additional research 5UPPOrt as they arise. The trustees are also conscious of on-going cash-flow requirements during a challenging time where historical fundraising methods are raising less income and where new methods of fundraising are being tested at higher cost. All things considered, the trustees believe it appropriate to continue to explore investment opportunities as they present themselves, with a view to maximising return on its deposits. During 2024, multiple deposits were made into the CAF Charity Deposit platform to the maximum value of £85,000 each over a 3-4-month term to maximise investment return on surplus funds. Reserves Policy To safeguard the need for sufficient funds to cover ongoing management, administration, and support costs, as well a5 respond to further grant requests that might arise, the Board aims to maintain unrestricted, free reserves at a level that equals 3-6 months of operating and charitsble expenditures1£417,658 - £835,316). On 31 December 2024, the charity held free reserve5 of £2,039,672 (unrestricted funds less tangible fixed assets). This equates to approximately 15 months of anticipated 2025 operating and charitable expenditures. Whilst this is significantly more than the policy level, the trustees are committed to strengthening existing income streams whilst diversifying fundraising activities to reduce relia nce on single sources. It is accepted that this will take investment in activities where the accuracy of predicting response rates, in terms of volume or value of gift, will be more challenging in the first instance. Therefore, these additional reserves will enable us to explore avenues of diversification of income streams, and to develop the charit￿5 objective activities for fLrture sustainability. Going concern The trustees consider that there are no material uncertaintie5 about the charity's ability to continue as a going concern. The trustees have made this assessment for a period of at least one year from the date of the approval of these financial statements having considered known commitments, forecasts and projections and possible pressures on income generation. After making these considerations, the trustees conclude that there is a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future. The charitable company therefore continues to adopt the going concern basis in preparing the financial statements. Our focus in 2025 and beyond Our focus for 2025 is very much on ensuring that we have the necessary funds to build a resilient and sustainable organisation that can meet the ongoing, and ever-changing, needs of our beneficiaries. Whilst we recognise that the charity sector continues to be a challenging space, industry reports do offer some little nuggets of hope. Take up of mass participation events and community fundraising activities appear to be on the 22 TRUSTEES ANNUAL REPORT FYE2024

(;? Diabetes ftèseard) Wellne55 Foundètion increase especially with younger people, a community that we are working hard to reach. At the end of 2024 we secured a debenture for 20 TCS London Marathon places for the next 4 years. This was a big win for our small community fundraising team of 2 who are intent on maximising this opportunity alongside a growing schedule of home-grown and third-party attivities. With investment in individual and sustainable giving programmes, as well as a focus on securing appropriate partnerships and sponsorships, we are intent on reversing the negative impact that both the pandemic and the economic climate have had on our ability to diversify and develop our fundraising portfolio and ultimately deliver Research and Wellness programmes that meet the needs of the diabetes community today and in the future. To do this effectively, we plan to- Broaden skill base in the Board of Trustees and diversify representation of the community that we serve. Review current operations, pro￿55e5 and procedu￿5 to ensure that we are maximising opportunity to create sustainable income streams and delivering relevant beneficiary services. Increase visibility of DRWF as an organisation that packs a punch above its weight in delivering benefit for our diabetes community by developing meaningful partnerships that align with our mission, vision and values and help us to extend our reach of target audiences. Elevate credibility of DRWF programme activities through clear and concise impact assessment, and consistent marketing messages that enable us to 'cut through the noise, in a competitive third sector. Continue to identify way5 in which to create costryefficiencies and effect organisational change within the charity to make for an organisation that can navigate an ever-changing landscape and is robust and fit for the future. 23 TRUSTEES ANNUAL REPORT FYE2024

Diabetss Research Wellne55 Foundation Reference and Administrative Details Charity Number: 1070607 Company number". 03496304 ReElStered Office., Building I(￿) Langstone Park Havant, Hampshire P09 ISA Tel.. [phone] Website: drwf.org.uk Trustees & Directors: Mr W. Michael Gretschel (Chairman- deceased Dec 24) Mr John Alahouzos (Chairman Dec 241 Mrs Valerie Hussey (retired March 2024) Mr Steve Jones Dr Shivani Misra (retired February 2024) Mr Christian Gretschel Mr Adrian Durelli (elected March 2024) Chief Executive- Mrs Sardh Tutton (Bone) Advisers Bankers.. Barclays Bank PIC I Churchill Place London E14 5HP Sol icitors: Blake Morgan LLP New Kings Court Tollgate Chandlers Ford Eastleigh S053 3LG Secretary: Blake Morgan Company Secretsry Services Auditors: Moore Kingston Smith LLP th 6 Floor, 9 Appold Street London EC2A 2AP 24 TRUSTEES ANNUAL REPORT FYE2024

Oiabe*5 Resear(h Et Wellness Foundation Structure, Governance & Management Governing Document - The Diabetes Research and Wellness Foundation, also known a5 DRWF, is a registered charitable company (Registered Charity No. 1070607 and Company No 03496304} limited by guarantee and governed by its Memorandum and Articles of Association dated 15 January 1998 and amended by special th nd th re501utions passed on 15 June 1998, 2 December 2001 and 24 April 2005. Recruitment & Appointment of Trustees The charity trustees are also the directors of the company for the purposes of company law. As dictated by the charity's Articles of Association, directors are appointed by the Company Members. Any person desiring to be admitted to the membership of the company is required to apply in writing. No person shall be admitted until approved by resolution passed in accordance with the Articles of Association by the existing members, who hold absolute discretion as to the admission of any person. The Trustees of the charity, being mindful that the board should offer a diversity of skills to fulfil statutory and fiduciary duties, are open to recommendations for new board members. The business and medical/health related skills within the existing board member pool are supported by personal experience of diabetes, which assists the board in ensuring that objective activities meet beneficiary need. Additionally, the board is supported in its decision-making processes by a Research Advi50ry Board, which has an independent Chairman. The RAB members review applications and make recommendation for research funding awards. An Editorial Advisory Board provides support to the provision of health and social care information. Both boards are made up of clinicians, scientists and other 'experts' in the field of diabetes and related health and strengthen the services that the charity offers its beneficiaries. All board members are subject to'conflict of interest, policies and processes. Trustee Inductlon and Training - Newly elected Trustees receive an Induction Pack that outlines the role and responsibilities of the Trustee, along With a history of the structure and purpose of the charity. The pack includes a copy of the governing document and contact details of all board members, There is also an outline of the Chairman of the Board's role and responsibilities along with details of the executive officer taking responsibility for the daily management of the charity. Trustees are required to comply with the eligibility requirements set out by Charity Commission and to review and update an annual Register of Interests. Trustees are kept up to date with various governance publications and notices from appropriate professional advisory memberships. Additionally, trustees might be advised of appropriate Eovernance courses that they mav benefit from attending to ensure diversity and continuity of knowledge and skills within the Board. Newly elected trustees are invited to attend a Review Meeting with the chair, after an agreed time lapse, to feedback their first impressions and address any concerns. Trustees are actively encouraged to participate in the charitV'S Outreach programme of educational events. Governance- The strategic direction and policy of the charity is the restx)nsibility of the Board of Trustees. At the start of 2024 six trustees served on the Board. from a variety of professional backgrounds relevant to the work of the charity. During the year there were two retirements from the Board and one new election to the Board. Additionally, the existing Chairman of the Board passed away in December 2024 therefore a new Chairman was duly elected in December 2024. The B03rd meets routinely throughout the year post-quarter end to review activities and management accounts. Additional meetings are organised as reqlsired. Historically, the Board would meet at least once per year in person however this changed durinE the Covid-19 pandemic due to travel restrictions, 25 TRUSTEES ANNUAL REPORT FYE2024

Diabetes Research WeLlne55 Foundation with all meetings being held virtually. There was I face-to-face Board meeting in 2024 with all other meetings being held onlir)e. The Chief Executive carries out the daily operations of the charity and is responsible to the Board of Trustees. Connected & Related Partles - DRWF co-operates on several intellectual matters including sharing articles and reports with the Diabetes Research and Wellness Foundation Inc., a 501C3 Not for Profit Company operating in the United States. Association pour la recherche sur le diabete {A-rd) in France. Insamlingsstiftelsen Diabetes Wellness Network Sverige (Swedenl,. Diabetes Wellness suomi (Finland) and Diabetes Wellness Norge {Norwayl. These organisations are completely autonomous and independent with no legal connections. Mr. John Alahouzos is the Chairman of the Diabetes Research and Wellness Foundation in the UK and is also Chairman of DRWF Inc (USA). He is also Chaimian of the Board of A-rd (Francel, and a Board member of DWNS (Swedenl, DWS (Finland) and DWN (Norway). Mr. Christian Gretschel is a Board member of Diabetes Research & Wellness Foundation {UKI and serves on the Board of A-rd (France) The Chief Executive of the Diabetes Research & Wellness Foundation, Sarah Tutton, serves on the Board of DWN (Norway). Links between these independent organisations, has proved invaluable to the charity in helping to strengthen it's international presence, for the purpose of supporting diabetes research programmes and global awareness activities. A Register of Interests for Board Members and Key Management Personnel is maintained and reviewed on an annual basis. Remuneration Policy for senior staff - The Trustees, who are also the directors, and the Chief Executive Off icer comprise the key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day-to-day basis. All trustees give their time freely and no trustee received remuneration in the year. Details of trustees. expenses are disclosed in note 12 to the accounts. Related party transactions are disclosed in note 20 to the accounts. The salary of all staff, including the chief executive officer, is reviewed annually and normally increased in accordance with average earnings. In view of the nature of the charity, its Size and Structure, the trustees undertake a benchmarking exercise, using online research/tools, comparing the chariws salaries against pay levels offered for similar roles within other charities and companies. The benchmark is the mid-point of the range paid forthese similar roles with consideration given to workload, level of responsibility, anticipated rate of inflation and other published research on third sector rates of pay. The charity considers that its remuneration policy- Ensures delivery of the charity's objectives Attracts and retains a motivated workforce with the skills and expertise necessary to ensure organisational effectiveness. Is equitable and coherent across the organisation. Reflects the purposes, aims and values of the charity. Ensures that pay levels and pay increases are appropriate inthe context of the interests of our beneficiaries. 26 TRUSTEES ANNUAL REPORT FYE2024

Diabetes Research Weline55 Foundation Risk Management- The Trustees have examined the major Strategic, business, reputational and operational risks that the charity faces. This involves identifying specific risks; asse551 ng their li kel ihood of occurrence and potential impact- determining what steps could be taken to mitigate those risks and delegating responsibility to key staff for overseeing management of the associated controls. The risk register is reviewed annually to ensure the adequacy of Internal control mechanisms. Our approach to risk assessment and management is evidenced across the organisation and throughout our activities. The risk register was circulated to the Trustees for review and scoring in September and resulting risks th discussed at a Board meeting held on 24 October. The Board considers that the major risks facing the charity at present, are- Fundraising Competition for support Dependency on income streams Demographic of supporters Program development including activities outside of objectives Location The past few years have been incredibly challenging for all charities, with clear impact on fundraising activities and attrition in channels that, historically, have been very solid in their return. The charity is focused on diversifying activities to reduce reliance on unpredictable or single income streams which mean5 reaching a wider demographic of potential supporter/beneficiary providing opportunity and choice of how to engage. The fundraising landscape is highly competitive at present, with more charities than ever applying for grant funding and seeking out corporate sponsorship income; individual donors reviewing their financial commitments because of the rising cost of livin& and legacy income, which is an entirely unpredictable income source, contributing a high percentage of overall income. We are mindful that fluttuations in income could impact on our ability to deliver direct charitable activitie5 and so remain agile in our approach to protect our aims and objectives. New projects/activities are reviewed to ensure that they are consistent with our objectives, powers and terms of restricted funding lif applicable), but we are aware of this rnore than everas we develop the charities activities to ensure that we remain relevant to the diabetes community and its needs whilst aligning with potential partners. Remote working through the pandemic, as well as diversifying our fundraising activities and provision of beneficiary programmes through multiple channels, has heightened our sensitivity to the need and use of technology to remain relevant to our audiences, and the impact that a cyber breach could have on the charity. We rely on public trust and generosity to support our activities, so are mindful of the financial and reputational risk a cyber breach could have. The trustees consider that the Charity has robust internal procedures, systems and processes and believe that risk assessment is embedded throughout the organisation. 27 TRUSTEES ANNUAL REPORT FYE2024

Dtabwe5 Re5parth & Wellness F(sur**ation Trustees, respon<iblllties In relatlonto the financial statenwnts-The trustees, who are also dlrectors of Dlabetes Research and Wellness Foundation for the purposes Df company law. are responsible for preparing the trustees, annual report and the financial statements in accordance with applicable law and United Kingdom Accountlng standards (United Kingdom Generally Accepted Accounting PractiGe.} Company law requires trustee5 to prepare financ5al statements fot each financlal year that @ve a true and fair view of the state of the affairs of the charitable company and of the outgoing resource5 and applicatlon of resources. including the income and expenditure, of the charitable company for that period. In preparing these flnancial ststements, the trustees are required to: select suitable accounting policie5 and then apply them consistently. observe the methods and principles in the Charities SORP. make judgements and estimates that are reasonable and prudent. state whether applicable U K Accounting Standards have beon followed. subject to any material departures d15closed and explained in the financi31 ststements. prepare the financial statements on the golng concern basis unles5 it is inapproprlate to presume that the charitable company will continue in business. The trustees are responsible for keeping proper accounting records that disclose wlth reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Art 2006. They are a150 re5ponSiDle for safeguardin8 the a55ets of the charitable company xnd hence for taklng reasonable 5tep5 for the prevention and detection of fraud and other irregularities. n so far as the trustees are av4Trre- there 15 no relevant audit information of whlch the charitrdble compan¢s auditor is unaware,. and the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information to establish that the audi-Lor is aware of that information. AudltoYs- Moore Kingston Smith LLP have indicated their willingness to continue in office and are deemed to be reappolnted in accordance with section 487121 of the Companie5 Att 2006. Small Company Exemptlon-This rerJ)rt has been prepared in accordance with the speclal provislons of Part 15 of the Companie5 Att 21x16 relating to small companies. On Behalf o Tru5tee5 Alahou205 Chairman Dated 28 TRUSTEES ANNUAL REPORT FYE2024

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF DIABETES RESEARCH AND WELLNESS FOUNDATION Opinion We have audited the financial statements of Diabetes Research and Wellness Foundation {'the company,) for the year ended 31 December 2024 which comprise the Statement of Financial Activities, the Summary Income and Expenditure Account, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including significant accounting policies The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard Applicable in the UK and Republic of Ireland, (United Kingdom Generally Accepted Accounting Practice). In our opinion the fi'nancial ststements" give a true and fair view of the state of the charitable company's affairs as at 31 December 2024 and of its incoming resOur￿S and application of reSoUr￿s, including its income and expenditure, for the year then ended., have been propedy prepared in accordance with United Kingdom Generally Accepted Accounting Practice" and have been prepared in accordance with the requirements of the Companies Act 2006. Basls for opinion We conducted our audit in accordance with International Standards on Auditing (UK) {ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditorfs Responsibilities for the audit of the financial statements *ction of our report. We are independent of the charitable company in accordan￿ with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC'S Ethical Standard, and we have fulfilled our other ethical responsibilities in accordan￿ with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Conclusions relating to going concern In auditing the financial statements. we have concluded that the trustees, use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concem for a period of at least ￿e1ve month5 from when the financial statements are authorised for issue. Our responsibilits'es and the responsibilities of the trustees with respect to going con￿rn are described in the relevant sections of this report. Other inforniation The other informab'on comprises the information included in the annual report, other than the financial statements and our audito¢s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not @xpress any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whelher there is a material misstatement in the financial statements themselves If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 29

We have nothing to report in this regard. Opinions on other matters p￿scrIbed by the Companies Act 2006 In our opinion. based on the work undertaken in the course of the audit.. the information given in the trustees, annual report for the financial year for which the financial statements are prepared is consistent with the financial statements,. and the trustees, annual report have been prepared in accordan￿ with applicable legal requirements. Matters on which we are required to report by exception In the light of the knowledge and understsnding of the company and its environrnent obtained in the course of the audit, we have not identsfied material misstatements in the trustees, annual report. We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion= adequate accounting records have not been kept, or retums adequate for our audit have not been received trom branches not visited by us., or the financial ststements are not in agreement with the accounting records and returns., or certain disclosures of trustees, remuneration specified by law are not made-, or we have not received all the information and explanations we require for our audit. or the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the trustees, annual report and from preparing a Strateg￿ report. Responslbilities of trustees As explained more fully in the trustees. responsibilities statement Set out on page 28, the trustees (who are also the directors of the charitable company for the purposes of company lawl are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is ne￿$Sary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial ststements. the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going con￿rn basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so. Auditor's Responsibilities for the audlt of the financial statements Our objectives are to obtain reasonable assuran￿ about whether the financial statements as a whole are free frorn rnalerial misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assuranc@ is a high level of assuran￿, but is not a guarantee that an audit conducted in accordance with ISAS (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. As part of an audit in accordance with ISAS {UK) we exercise professional judgement and maintain professional scepticism throughout the audrt. We also.. Identify and assess the risks of material misststement of the financial stslements, whether due to fraud or error, design and perform audil procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentalions, or the override of internal control. 30

Obtain an understanding of intemal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the charitable company's intemal control. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees. Conclude on the appropriateness of the trustees, use of the going con￿rn basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditorfs ieport to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor s report. However, future events or conditions may cause the charitable company to cease to continue as a going concem. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whetherthe financial ststements represent the underlying transactions and events in a manner that achieves fair presentation. We communicate with those charged with govemance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. Explanation as to what extent the audit was considered capablo of detecting irregularities, including fraud Irregularities, including fraud, are Instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures a￿ capable of detecting irregularities, including fraud is detailed below. The objectives of our audit in respect of fraud, are- to idents-fy and assess the risks of material misstatement of the financial statements due to fraud", to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due io fraud, through designing and implementing appropriate responses to those assessed risks,. and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company. Our approach was as follows.. We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charilies Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council. We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance. We assessed the risk of rnaterial misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance. We inquired of management and those charged with governance a5 to any known instances of non-compliance or suspected non-complian￿ with laws and regulations. Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of 31

management and those charged with governance and obtaining additional corroborative evidence as required. There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intents.onal misrepresentations, or through collusion. Us• of our report This report is made solely to the charitsble company's members. as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, for our audit work, for this report, or for the opinions we have fonned. oorL Izini£kn q-,14 LLP Date.. 15 August 2025 Samir Chandoo (Senior Statutory Auditor) for and on behalf of Moore Kingston Smith LLP, Statutory Auditor 6th Floor 9 Appold Street London EC2A 2AP 32

Diabetes Reséarch and Wellness Foundation Statement of Financial Activitiès Ilncorporating the Summary Incom# and Expenditure Account For the year ended 31 Dècèmber 2024 2C24 roTAL Unrestsicied Fundg Re5triGIEd Fund$ 2023 TOTAL Fun Incom Doftalion8 and Leg8ues Charita￿e Acuvilies other chartt8￿e Tiadlng Act￿￿8¥ Investmènts In¢om6frorn CharitalleAthitEs (ther Incom8 Totsl Income 1,157.904 80.015 55.D49 .351 1,350,319 20.171 1 370 496 27.953 135,578 1,185.857 215.593 $6.049 56,351 1.513.8 2C.177 1,191.928 96.$4S 44.9S0 29,057 1,362,491 20.775 1 383 266 21,974 253.613 1.213.9D2 350.159 44,960 29,057 1.638.078 20.775 1 658 653 163.S31 275,587 163 531 275 587 EXpondIts￿ On: R￿sIng Funds Charii8t4e A¢bvitse8 Other 265.71B 1.300.062 265.718 1.528,324 378.848 1252,851 378.648 1.476,419 226.262 213,56e 1 565 780 226 262 1 792 042 1 e41499 213588 1 855 087 Netlncorne 258 015 258 233 196 214 Transfèr betr￿￿ Pund5 tlet Movement ITr Funds 195284 258015 258 233 Totsj Funds brought forw 2.243,742 70.684 2.314,426 2,501.975 2,510,640 Total fundg ¢arrled forward at31 D￿rnber 2024 2 048.458 2056411 2 243 742 70 884 2 314 426 The￿ were no r8¢(KJnised 9ans or knsse8 Otherth the defd rep￿10r1hefiTra￿caI year. Al 8LaNitEs In the yew rdate to continling operatiDn$. The axornpanylng notes form partofthese finaw81 st*emerrts. 83

Dlabetos Research and Wellness Foundatlon Balance She8t As at 31 Dec8mb8r 2024 Note 2024 2023 2023 Flxod knots Tangible A$88 15 CurrontAts8èta 8.788 12,175 Debtors Investments Cash at bank and In hand 16 655.293 433.101 1.418.968 808.379 424258 1,463,331 1507.362 2,696,968 Cr￿lt01 .' AmtX4nts tslllng duo withln on• ye•r 17 1459.737) {393.71 Currenl Assets Totsl Net Assets 2,047,625 2056411 2,302,251 2 314426 Restslctsd Fund General Reserve 19 19 7.953 2.048.458 70.684 2,243,742 23144 fina￿1￿1 slatement8 have been rKepar8d in aco)rdance with proy[si￿ applKabte to compantes subjeGt Io thè rnll ¢ompaThes regime Part 15 of Ihe Corrpantes kt 2006 a￿1 with the FR8 102 Gharty SORP. The financkl statemeAts weft apprnved, and athrW1sp￿ for distribuuon. TNsteeg on .0. s.l 0 21 £0 15 and Signed on their behalf by.. .. Tfustee The accompanyaig notes fomi an integral part of tsse $tatwna Company numbor: 03496304 34

DIa￿teS Research and Wellness Foundation Statement of Cash Flows For the year ended 31 December 2024 2024 2023 Cash used In Operating Actlvttles 23 191,8711 164.519 Cash Flows from Invastlng Actfvities Interest Dn Bank Dèposit Investsnents Fixed Assets 56,351 18.8431 29,057 1424,2581 19,8501 47.508 1405,0511 Cash Flows from Flnanclng Actr¥itiÈS Change in Cash and ¢ash gqufval•nts in the year 144,3631 1240,5321 Cash and cash equivalents brought forward 1st January 1,463,331 1,703,863 Cash and cash equivalents at 31st December2023 1418968 1463 331 35

Diabetes Research and Wellness Foundation Notes to the Financial Statements For the year ended 31 December 2024 Accounting Policles The financial ststements have bèen prepared in accordance the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) The Charitable Company is a public benefit company for the purposes of FRS 102 and Iherètore the Charity also prepared its financtal statements in accordance w4th the Statement of Recommended Practice applicable to charities preparing their accounts in accordan￿ with the Financial Reporting Standard applicable in Ihe UK and Republic of Ireland (The FRS 102 Charities SORP). the Companies Act 2006 and the ChariUesAct 2011. The Irustees have assessed whether the use of the going cOn￿M basis is apwopriale and have considered possible events or conditions that might 12St significant doubt on the abilty ofthe charty to rL)ntinue as a going concern. The trustees have made this assessmenl for a period of at least one year from the date of approval of the financial statements. In particular the trustees have considered the charity's forecasts and projections and have taken account of pressures on donations income. After making enquiries the trustees have concluded thal there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The charity therefore conts'nues to adopt the going concem basis in preparing its finanaal statements. The finan￿al statements are prepared in steding. whith is the functional currency of the chanty. Monetsry amounts in these financial ststements are rounded to th8 nearest pound. The financial statements have been prepared on the historical cost convention, modified to include ￿rtain financial instruments at fair value. The principal accounting policies adopted are set out below. Critical accounting estimates and areas of judgement In the view of the trusle@s in applying the accounting policies adopted. no judgements werè required that have a significant effed on the amounts recognised in the financial statements nor do any estimates or assumptions made carry 8 significant risk ot material adjustment in the next finar￿181 year. The prtncipal accounting FKJlicies of the charity are set out below.. Income Incom6 is included on an accruals basis eX￿pt that donations under gift aid together with the assouated income tax recoveries are creditèd as income when the donations are re￿ived. Membership Subscriptions are apportioned across the membership subscription period. Income from gift aid repayment ciaims is only included for claims which have been submitted for tsx periods ending on or before the year end and vthen the re￿Ipt of this inGome is certain. Legacles Legacies are recognised following probate and once there is suffictent evidence that receipt 15 probable and Ihe amount of the legacy receivable can be measured reliably. Where ents'tlement to a legacy exists but there is uncertainty as to its receipt or the amount receivable, details are disclosed as a contingent asset until the criteria for income recognition are met Publlc Donatlons and Gifts-in-Klnd Incoming resources in the form of Gifts-in-Kind are included in the Statement of Financial Activtties only when assets donated to the charity are distributed. Gifts-in-Kind are donab-ons of commodities directly usable in charitable programmes, such as food, blankets, books, agricultural and medical supplies. The Charity has an internationally recognis&d and accepted monitoring programme in place lo ensijre that comm(Kiities are appropriately valued at wholesale or less, culturally appropriale for the designated programme, and can be both properly shipped and distrtbutsd gratis to th6 designated beneficiaries. 36

Diabetes Research and Wellness Foundation Notes to the Financial Statements (Continued) For the year ended 31 December 2024 1 Accounting Policies (continued) Expenditure Expenditure, which is charged on an accruals basis, is allocated between: o expenditure incurred directly in the effort to raise voluntary contributions (raising funds); o expenditure incu rred direclly to the fulfilment of the charitys objectives (charitsble aclivities)., Charitable expenditure comprises all the expenditure incurred by the charity in Meeting its charitable objeclives and is further analysed between: grants payable in the furtheran￿ of the charivs objectives o costs of activities in furtheran￿ of the charitys objectives support costs of the charity Cost Apportionment Where items of expenditure involve more than one cost category these costs have been apportioned on a reasonable basis as detetinined by the trustees. One particular area where the cost is material to the charity is in the production and distribution of direct mailing8. One of the purposes of the mail shot is to develop a datsbase of names of people with a particular interest in the activities of the charity and its charitable objects. It is held that individuals who make a £10 or greater donation. in response to the mailing, have a degree of interest in diabetes. They are interested because they suffer from diabetes, know somebody who does or could themselves be at risk of developing the condition. These are precisely the people whom the charity is trying to help and consequently they re￿1ve the benefits of the educational material provided by the charity. These high interest individuals constitute 25% of the total responses. so the charity allocates 25% of the cost of the mailing to costs in furtherance of the charity's objects. Furthermore the remaining expenditure has been allocated on the basis of whether the educational content of the individual mailing is significantly high enough so as to be material. When this holds true the remaining cost of the mailing is allocaled on a pro-rata basis comparing the educational content (costs in furtherance of th& charity's objects) to the fund raising content (costs of generating funds). The educational content is determined by the amount of text and space on each mailing that is dedicaled to material of an educational nature. Telemarketing expenditure is allocated in a consistent manner with mailings, as described above, hence the charity allocates 250/0 of the cost of the telemarketing calls to costs in furtherance of the charity's objectives, with the remaining expenditure allocated on the basis of whether the time spent during the telephone call is in accordance with the charity's objects or otherwise. Fund raising expenditure i.e. Text that may induce a donation from the recipient, is allocated upon the basis of the volume of the text and space that is nol related to text of an educational nature. Support costs comprise all other overtiead cosls for the running of the Charity as an organisation. Fund Accounting Designated funds are unrestricted funds eamiarked by the Trustees for particular purposes. The aim and use of each fund is set out in the notes to the financial statements. Unrestricted funds are donations and other incoming resources received or generated for expenditure on the general objectives of the charity. Restricted funds are donations received from a donor who has specifEd a particular area of the charity's work to which the donation should be allocated. 37

Diabetes Research and Wellness Foundation Notes to the Financial Statements (Continued) For the year ended 31 December 2024 Accounting Policies {continued) Grants Payable Grants are rewgnised when they become due for paymenL Included within the Statement of Financial Activities is the cost of grant instalments that are payable to charltable organisations l indivtduals in accordance with the charity's governing instruments, together with any grants payable for the year. bul not paid by the year end date. The value of grants awarded whi¢h are subject to the completion of a future yèaff s performance is disclosed as a Financial Commitment in Note 21. Tangible Flxed Assets and Depreciation Depreciation is calculated to write down the cost less estimated residual value of all tangible fixed assets held for charity use by equal annual instalments over their expected useful economic lives. The rates generally applicable are: Office equipment, fixtures and fittings 5-7 years straight line All tangible fixed assets costing more than £250 are capitalised at their cost to the charity- Foraign Currencies Transactions in foreign currencies are translated at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities in foreign currencies are translated at the rates of exchange ruling at the balance sheet date. All exchange differences are dealt wilh through the statement of financial activities. Leasing Commitments Rentals payable under operaling leases are charged against income on a straight line basis over the lease term. Other Flnancial Instruments i. Cash and cash equivalents Cash and cash equivalents include cash at banks and in hand and short temi deposits wth a maturity date of 90 days or less. 11. Inveslments Current asset investments include deposits with a maturity date of more Ihan three months. 111. Debtors and Crèditors Debtors and creditors receivable or payable within one year of the reporting date are carried at their at transaction pri￿. Debtors and creditors that are receivable or payable in more than one year and not subject to a market rate of interest are measured at the present value of the expected future receipts or payment discounted at a market rate of interest. 38

Dlabetes Research and Wellness Foundation Notes to the Financial Ststements (Continued) For the year ended 31 December 2024 Donatlons and Legacles 2024 2023 Donations Lottery Programme Legacies Received 549,888 7,242 628,727 1,185.857 Induded in the above are restsicted donations and legaci8s of £27,953 (2023..IS￿ 681.335 7,942 524,625 1,213,902 Charitable Activities 2024 2023 Grants Re￿iVed Grft Aid Re￿Ip1S 135.578 80,015 215,593 261,S04 88,655 350,159 InclL¢ded in the above are restricted grants of £135,578 {2023.. £253,613) Othèr Charllable Trading Activities 2024 2023 Membership Subscriptions Event Fees and Sponsorship 6,1Q 49,943 56,049 7,392 37,568 44.960 Other income 2024 2023 mis￿lIaneouS Income 20.177 20.177 20,775 20.775 Fund Raising CLists 2024 2023 Caging Carriers Computer Charges Lettershop and Data Postsge and Shipping Printing Publicity Communty Fundraising Mail Pack Premiums Lottery Costs Staff Costs (see Note 111 Sw8epslake Wlnrters 79.11S 79 2.736 1.745 9.869 403 681 21,662 1s,972 3.237 130.444 225 265.718 171,167 3,474 6,034 5,629 38,176 11.665 1,163 16,005 11,220 3,570 95,745 14,800 378,648 Charitable Activities 2024 Direct Expenditu (Note 9) 2024 Grdnts Awards {Note 8) 2024 Support Costs {Note qo) 2024 Total Research into thé R¢li8f of Diabetes Raising Public Awar9ness of Diabetes 398.189 415.949 614,138 712,186 1,526,324 712,186 712.186 398,189 415,949 2023 Dlrect Expenditure (Note 9 2023 Grants Awards {Not& 81 2023 Support Costs {Note 10) 2023 Totsl Research into the Relief of Diabetes Raising Public Awareness of Diabetes 311,343 404,867 716,210 760,209 1,476.419 760.209 760,209 311.343 404,867 39

Diabetes Research and Wellness Foundation Notes to the Financial Statements (Continued) For the year ended 31 December 2024 Grant Awards 2024 2023 University of Oxford Cardiff Univ6rsity- Non Clinical Fellowship 2021 University of East Anglia - Clinical Fellowship 2021 University College LondonlLiverpool Universty- Non Clinical Fellowship 2022 2024 Pump PrimiThJ Awards BHR Lld 172,614 5.415 79,003 126,407 64.977 79,002 56,719 66,853 119,982 900 434,633 337,239 Less.. Unclaimed grants written back (36,444) (25,896) 398 189 311343 40

Diabetes Research and Wellness Foundation Notes to the Financial Statements (Continued) For the year ended 31 December 2024 9 Direct Charltable Expenditure 2024 2023 Staff Costs (see Note 11) Postage Printing Publicty Mail Pack Premiums Educational Events Carriers Grant Costs Lettershop and Data 327,458 88,321 23,490 371,825 156,848 68,964 1,505 44,461 81,099 13,766 2,570 19,171 760 209 151,978 108,780 750 404 11,005 712 186 10 Support Costs 2024 2023 Other Staff Costs Professional Costs Management Charge Office Expenses Establishment Expenses Bank Charges and Interest Paid Foreign Exchange (Loss> Depreciation Irrecover8ble VAT Amounts paid to Auditors Company Secretarial Fees Board Meeting Expense5 & Trustee Expenses Other Overhead Costs 1,565 22,405 152,450 70.981 46.156 5,554 2,967 3,389 66,398 21,916 513 10,512 11,143 415 949 3,278 29,097 156,408 72,997 33,194 5,283 5,853 3,516 66.292 22,975 513 180 5,281 Support Costs are allocated to the Charitable expenditure of the charity in proportion to the direct cost of the activity 11 Wages and Salaries 2024 2023 Wages and Salaries Social Security Costs Pension Costs 410,414 34,206 13,282 457,9Q2 419,169 34,355 14.047 467,571 The key management personnel of the charity are the Trustees and the CEO. The total amount paid for key management personnel was £74,652 (2023.. £71,732). 2024 2023 No. No. The number of higher paid employees was in the band: £60,000 - £70,000 Pension contribLrtions payable for the above individual was £2,887 (2023". £2.776). The number of employees at the end of the year was 13 (2023.. 13). 41

Diabetes Research and Wellness Foundation Notes to the Financial Statements (Continued) For the year ended 31 December 2024 12 Payments to TTUStees No trustee or person wrth a family or business connec*ion vrith a truste6, re￿iVed remuneration in the year, directly or indirectly, from the charity. Reimbursement to Trustees for Travel and Meeting Costs were £6.551 for 3 trustees (2023. £nil). 13 Surplus of Income over Expenditure 2024 2023 The surplus of income over 6xpenditure ts stated after charging= Auditors, RemurTeration'. Audrt Fee ￿lating to the Financial Year In respect of non audit services Operating Lease rentals Plant & Machinery Other Assets Foreign Exchange Loss Depr@ciation 23,995 1,350 22.900 1,250 3,185 22,871 2,967 3,066 16,719 5,853 3.516 14 Taxation The company, being a registered chanty, is not liable for corporation tax in respect of its charitable operations for the year. 15 Tangible Fixed Assets for Charfty Use Office equipment, flxtures and fittings Cost At 1 January 2024 Additions in Year Disposals in Year At 31 De￿mber 2024 18,956 18,956 Depreciation At 1 January 2024 Provided in the ye8r Elirninaled on Disposal At 31 December 2024 6,781 3,389 10,170 Net Book Valu8 At 31 Detsmber 2024 8786 At 31 December 2023 16 Debtors 2024 2023 Trade Debtors Other Debtor5 Prepayments and Accrued Income 7,740 8,792 638,761 655 293 68,777 5,261 734,341 808 379 All Debtors except prepayments are financial instruments and are measured at settlement valuè 42

Diabetes Research and Wellness Foundation Notes to the Financial Statements (Continued) For the year ended 31 December 2024 17 Creditors '. Amounts lalling duè within one yèar 2024 2D23 Trade Creditors Grants Payabfe Ise& below) Accruals and Defefreo In(x)me Tax and Social S￿￿rItY Olher Cr¢ditors 42,118 363,542 40,515 13.562 44,805 248,706 82,274 17,932 459 737 393 717 All Credthr5 except dolerr¢d iKome are ￿anCA81 instruments a￿1 are measured at sthm8nl value Reconciliation of Grants Payabl•-. Comrnriments 811 January 2024 Grants Payable for th8 Year {see Note 81 Grants PaKI during Year 248,706 398,189 283.353 210,955 311,343 273,592 363 542 In additk)n to the 8mounts ccffimitied and accr￿ not￿ above. the truste&% navè also a￿t￿rised tre rxxitinuation of certain grant8 whth are suiigct lo th& rec4plant fuifrfkng ￿r[aIn conditions. Th8 di15 ofthese further ￿Mm￿MentS can be found in Note 21. 18 Deferred Income 2024 2023 Deferred Incorne 8IFWD 1st January 2024 Released to Income In Year Ineome Defer￿￿ In Year D8ferr8d Incorne CJFWD 315t DeGetnber 2024 5,576 15,$761 8,238 3,3SO 13,3601 5,576 Deferréd In¢ome cornpnses.. - Newsletter Membership Sub5cripb"on5 whith are renewable annuaty on a rolling 12 basi$ - Comrnunity fundraised donations that relate to 2025 events. 19 R￿rIeS Batanc• at l January 2024 I￿orne in Year ExpendÈture In Year Net Movement In Year Balance at 31 O¢¢¥mb•r 2024 Restrlctecj Fund relating to Dkqbetes Research {grant) Restricted Fund relatng to The BBJ Give Chrisbytas Chalengg Rèstricted FuThJ relating to 0￿beteS Research lacyl General Reserve 48.710 21.974 135.578 7.953 20.wo 1,37a.496 1784.2881 121,9741 120.0001 1 585,780 1,792,042 14B,719) 114,021) 7,953 2.243.742 2314426 195,284 258 015 2.048.458 2056411 Balance at 1 January 2023 Income Sn Yoar Expenditure in Year Net Movèment In YÈar Balance at 31 Decembgr 2023 Restricted Fund relating to t*thte5 Researc Restncted Fund relating lo The Big Givè Christmas Chalenge Restn¢ted Fund relating to Dithtes Research Ilegacy; General Re￿rve 253.613 21.974 1204,9031 ie.6651 48,710 13,309 48,710 21,974 8.665 2.501.975 2510640 1,383,266 1 658 853 1,641,499 1 855 067 258,233 1￿214 2,243.742 2 314 426 During 2024 the charity partt4P8tsd in the Big GI￿ Christmas Challwge 2024 to rdise fvnth fora Purnp Priming Reswth Grant. The fund5 recewed In thè year was £7,95312023 £21.9741. Net Assets by Fund Unre5tri¢ted Restricted Total Tangible Assets Current Assets Current Li8bilitEs 8,786 2.499,409 459.737 2,048.458 8,786 2,507.262 459,737 2,056,411 7,953 7.953 43

Diabetes Research and Wellness Foundation Notes to the Financial Statsments {Continued> For the year ended 31 December 2024 20 Payments to Connected Charfties Nature of Retatlonship 2024 2023 Connectèd Charlty Naujre gf Tronsaction5 Total Balance at Totsl Balance at tra￿3￿ctionS the yearend tronsa¢tkms the year end In the ye In the year Di#￿t8$ Research and Welness FouftdatK)n Inc. 152.450 156,408 Pknnagement tharges in retation to the sharing of artides and Staff. Nature of Relationships 1 Diabetes R8sèarc) and Wdkn8ss Foundaton Intr 15 ￿rn￿etely separa￿and independent vjilh no legal connecthons, Mr. John ￿a￿DuZ0s srts on the Board ol Tru8tees ofthe aSS￿la￿ charty In the United States. Futhèrdetalls regardlng the rIC￿Shlp can befound in the Trijstees Rewrt. 21 Fi￿ncEal Commttments The charity has finallcial commitsnents of £277,195 12023. £404.517} forgwts aUth￿sed bul nol as expenditure for the yeat ended 31 Dgcèmbèr 2024. Bs they a￿ subjectto the reapiert fuffilling ￿rtain ￿n¢1￿"0ns. The amO￿ts payatje a￿ 8$ lollw. 2024 2023 P8yable in 2024 P8y8ble In 2D25 PaYal￿e in 2D26 P8yabie in 2027 382,270 22,247 1S3,007 97.840 26.348 277195 404 517 22 0￿ratIng Leases At 31st December 2024, the ¢narity ha$ txmmitrnents under oFwatirvJ le89es as follcw3'. 2024 2024 2023 2023 offt T￿￿t0 Fiwe Years Wrthin one Year Two to Five Years Land and Buildings OtherAsssts 24,950 2.586 1,982 4,658 24,950 2,483 26.932 1.852 Total 27.383 28,784 The Charity's Offi￿ lease comnne¢d on 31st January 2Q24 with a temi oflhree yeats and a disctunied Per￿ of the first tyyee monlhs during which the rent payable was £nil. 23 R8¢on¢lllatlon of Movèm¢rt In Funds to Nèt Ca8h Flo¥Y f¥Dm 0￿￿n9 A￿1vIlle¥ 2024 2023 Net Movement in Funds- Surplu51lDefic Add bad( Depreoation charge Deduct InlerEst Income showTr in In¥esting AL*vilies OEcrease1STrcreasel ￿n Debtor5 Inclea￿ (DeC￿ease) In Creditors Net Cash uged in Operatsno ACtiV￿e$ 1258,0151 3,389 (5(J.3511 153.088 66 020 1196,2141 3,516 129,05n 397,220 10,9461 164 519 24 Mpmber5' Ltability The FotJndab"on Is a company Itmited by guararttee. In ts event oFwnding up. ts S n￿M￿￿$. I￿?bIlIty is linrted £1. 44